Search
Changchun High-Tech: Subsidiary GenSci's 128 Tablets Receive Orphan Drug Designation from the U.S. Food and Drug Administration
1 day ago /
Read about 0 minute
Author：小编
On March 24, Changchun High-Tech announced that its subsidiary, GenSci Pharmaceuticals, has received notification from the FDA that GenSci 128 Tablets have been granted orphan drug designation for the treatment of gastric cancer. GenSci 128 Tablets are a Class 1 chemical drug for therapeutic use, falling under the '505b1' category in the U.S. drug registration classification. This drug is a selective reactivator targeting the TP53 Y220C mutation, intended for the treatment of locally advanced or metastatic solid tumors harboring this mutation, including pancreatic cancer, gastric cancer, ovarian cancer, breast cancer, and colorectal cancer.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
